The vaccine against Covid-19 developed by the Pfizer and BioNTech laboratories is a real scientific success.
It is also unsurprisingly a huge commercial success.
Pfizer plans to sell 2.1 billion doses this year, generating $ 33.5 billion in revenue.
We are far from the $ 26 billion on which the American laboratory was counting in May, and the $ 15 billion estimated in February.
But, with the vaccination campaigns that are being set up all over the world, contracts are multiplying.
Last Friday, for example, the United States ordered 200 million additional doses.
"The speed and efficiency of our efforts with BioNTech to help vaccinate the world against Covid-19 are unprecedented, with now more than 1 billion doses delivered globally"
, welcomed Wednesday Pfizer CEO Albert Bourla.
To read also:
Vaccination: deliveries of Pfizer down and AstraZeneca shunned by the French
By comparison, the Moderna laboratory, which has also developed a messenger RNA vaccine against Covid-19, forecast annual sales of $ 19.2 billion in May. As for the American pharmaceutical group Johnson & Johnson, it anticipates $ 2.5 billion in revenue. However, unlike its competitors, Pfizer only sells its vaccine at cost price to poor countries. Johnson & Johnson and AstraZeneca have made a commitment to do so for all their customers during the pandemic.
The laboratory's sales could grow further because Pfizer and BioNTech recommend the injection of a third dose of the vaccine to make it more effective.
“New studies show that a third dose has
more than five times the neutralizing effects against the
more than five times the
neutralizing effects against the
in young people and more than eleven times in older people
says Pfizer. The group and BioNTech could apply for an emergency marketing authorization by August.